Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

INO Therapeutics

M&A STATUS
401-500 EMPLOYEES
IPO LATEST DEAL TYPE (Cancelled)
2 FINANCING ROUNDS
Description

Manufacturer of late stage drugs for the treatment of heart and lung functions. The company's primary offering INOmax is used to carry oxygenated blood to the body tissues, and for the treatment of persistant pulmonary hypertension in the newborn.

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Acquirer
Primary Office
  • Six State Route 173
  • Clinton, NJ 08809
  • United States

+1 (908) 000-0000

INO Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore INO Therapeutics‘s full profile, request access.

Request full access to PitchBook

INO Therapeutics Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore INO Therapeutics‘s full profile, request access.

Request full access to PitchBook

INO Therapeutics Executive Team (2)

Name Title Board
Seat
Contact
Info
Daniel Tassé Chief Executive Officer
David Shaw President